Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study.

Background & Aims: Hepatic fibrosis due to chronic HBV infection has enormous socioeconomic impact. Besides strategies targeting virus elimination, prevention or reversal of liver fibrosis is amenable. Given the antifibrotic activity of interferon-gamma (IFN-gamma), a randomized open-labeled multicenter trial was initiated to test IFN-gamma in HBV infection.

[Clinical study of anti-hepatic fibrosis effect of IFN-gamma in patients with chronic hepatitis B].

Objective: This was an open, random, control and multicenter clinical trial. In the study, the anti-hepatic fibrosis effect of rhIFN-gamma and its side reactions were evaluated.

Methods: A total of 289 patients enrolled in clinical trial, 153 patients in trial group and 136 patients in control group.

[Clinical analysis of primary head and neck non-Hodgkin's ].

Objective: To research the clinical features of primary head and neck non-Hodgkin's lymphoms (NHL).

Method: 62 patients with primary head and neck NHL were analyzed in the positions of focuses, clinical aspects, diagnosis and treatment.

Result: Tonsilla palatina(25.

[Treatment of chronic hepatitis C by bicyclum, a randomized double-blind placebo controlled trial].

Objective: To evaluate the efficacy and safety of bicyclum, a China made new hepatocyte protecting agent, in the treatment of chronic hepatitis C (CHC).

Methods: Thirty-nine CHC patients matched demographically and clinically were randomized into two groups: bicyclum group (group A, n = 20) and placebo/bicyclum crossovergroup (group B, n = 19). Bicyclum 75mg/d or placebo was administered to these two groups respectively for 3 months.